Drugs / RGH-706
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05322096 | Sep 2022 → Apr 2024 | Prader-Willi syndrome | Gedeon Richter Plc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGH-706 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05322096 ↗ |
| Action | Inhibit | “MCHR1 antagonist” NCT05322096 ↗ |
| Route | Oral | “Oral administration” NCT05322096 ↗ |
| Target | MCHR1 | “RGH-706 is a novel, potent, and orally active MCHR1 antagonist drug candidate” NCT05322096 ↗ |